Citations

Clear

6273 citation(s) found for "To, Andrew".

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica, Alphonse E. , Groopman, John D. , Selaru, Florin M. , Wang, Xin Wei , Zhu, Andrew X. , Wei Wang, Xin , Groopman, John D , Gores, Gregory J. , Strazzabosco, Mario

Mayo Clinic

Hepatology | September 25, 2018 | Volume: 69 | Issue: 4 | Pages: 1803-1815

10.1002/hep.30289 | PMID 30251463 Get It

Intrahepatic cholangiocarcinoma (iCCA) has over the last 10‐20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide. The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates to seek greater mechanistic insights and more effective biomarker‐driven targeted approaches for managing and/or preventing this challenging liver cancer. In addition to discussing challenges posed by this aggressive cancer, this review will emphasize recent epidemiological, basic, and translational research findings for iCCA. In particular, we will highlight emerging demographic changes and evolving risk factors, the critical role of the tumor microenvironment, extracellular vesicle biomarkers and therapeutics, intertumoral and intratumoral heterogeneity, and current and emerging targeted therapies regarding iCCA. Specifically, recent evidence linking non–bile duct medical conditions, such as nonalcoholic fatty liver disease and nonspecific cirrhosis, to intrahepatic cholangiocarcinogenesis together with geographic and ethnic variation will be assessed. Recent developments concerning the roles played by transforming growth factor‐β and platelet‐derived growth factor D in driving the recruitment and expansion of cancer‐associated myofibroblasts within cholangiocarcinoma (CCA) stroma as well as their therapeutic implications will also be discussed. In addition, the potential significance of extracellular vesicles as bile and serum biomarkers and therapeutic delivery systems for iCCA will be described. An integrated systems approach to classifying heterogeneous iCCA subtypes will be further highlighted, and recent clinical trials and emerging targeted therapies will be reviewed, along with recommendations for future translational research opportunities. Established international CCA networks are now facilitating collaborations aimed at advancing iCCA translational and clinical research.
Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty
Gregory, Martin , Stwalley, Dustin , Hippensteel, K. J. , Loftus, Edward V. , Ciorba, Matthew A. , Deepak, Parakkal , Loftus, Edward V , Deepak, Parakkal , McKinnon, Andrew, Olsen, Margaret A A

Mayo Clinic

Journal of Crohn's and Colitis | September 22, 2018 | Volume: 13 | Issue: 2 | Pages: 182-188

10.1093/ecco-jcc/jjy148 | PMID 30256926 Get It

The association of physical activity before and after lymphoma diagnosis with survival outcomes
Pophali, Priyanka A. , Ip, Andrew , Flowers, Christopher R. , Link, Brian K. , Farooq, Umar , Allmer, Cristine, Cohen, Jonathon B. , Thompson, Carrie A. , Rosenthal, Allison , Witzig, T.E. , Link, Brian K , Farooq, Umar , Pophali, Priyanka , Larson, Melissa C. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: 1543-1550

10.1002/ajh.25288 | PMID 30230581 Get It

AbstractThe impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) survival was evaluated in a prospective cohort of newly diagnosed lymphoma patients (2002‐2012). We calculated Leisure Score Indexes (mLSI) from the self‐reported usual adult PA (baseline) and at 3‐years post‐diagnosis (FU3), grouping patients by active vs insufficiently active by the American Cancer Society PA guidelines. Associations of PA with survival were assessed using hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype, adjusted for age, sex, baseline BMI, and comorbidity score with change scores further adjusted for baseline PA. Three thousand sixty participants were evaluable at baseline and 1371 at FU3. Active patients had superior survival from baseline [HR (CI): OS 0.82 (0.72‐0.94); LSS 0.74 (0.61‐0.90); EFS 0.92 (0.82‐1.02)] and FU3 [HR (CI): OS 0.64 (0.46‐0.88); LSS 0.32 (0.18‐0.59); EFS 0.82 (0.61‐1.10)] compared to insufficiently active. An increase in mLSI from baseline to FU3 (vs stable mLSI) was associated with superior OS (HR = 0.70, CI 0.49‐1.00) and LSS (HR = 0.49, CI 0.26‐0.94).The continuous change in mLSI at FU3 was significantly associated with OS, LSS and EFS; maintained across subgroups and appeared linear. Higher PA among lymphoma patients at diagnosis and 3 years is significantly associated with OS, LSS, and EFS. Increasing PA after diagnosis is significantly associated with improved OS and LSS supporting an important role for PA in lymphoma survivorship and the need for intervention trials.
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma
Koehler, Jennifer W. , Miller, Andrew D. , Miller, C. Ryan , Aldape, Kenneth , Beck, Jessica A. , Corps, Kara N. , Frank, Chad , O’Sullivan, M. Gerard , Rissi, Daniel R. , Simpson, R. Mark , Woolard, Kevin , Shih, Joanna H. , Mazcko, Christina , O’Sullivan, M. Gerard , O'Sullivan, M Gerard , Porter, Brian F. , Brat, Daniel J. , Cornax, Ingrid , Giannini, Caterina , Horbinski, Craig , Huse, Jason T. , Gilbert, Mark R. , LeBlanc, Amy Kathleen

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 19, 2018 | Volume: 77 | Issue: 11 | Pages: 1039-1054

10.1093/jnen/nly085 | PMID 30239918 Get It

Population health challenges in primary care: What are the unfinished tasks and who should do them?
North, Frederick , Tulledge‐Scheitel, Sidna M. , Matulis, John C. , Pecina, Jennifer L. , Franqueira, Andrew , Johnson, Sarah S, Chaudhry, Rajeev , Franqueira, Andrew M, Pecina, Jennifer

Mayo Clinic

SAGE Open Medicine | September 18, 2018 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2050312118800209 | PMID 30245819 Get It

Background: There are numerous recommendations from expert sources that help guide primary care providers in cancer screening, infectious disease screening, metabolic screening, monitoring of drug levels, and chronic disease management. Little is known about the potential effort needed for a healthcare system to address these recommendations, or the patient effort needed to complete the recommendations. Methods: For 73 recommended population healthcare items, we examined each of 28,742 patients in a primary care internal medicine practice to determine whether they were up-to-date on recommended screening, immunizations, counseling, and chronic disease management goals. We used a rule-based software tool that queries the medical record for diagnoses, dates, laboratory values, pathology reports, and other information used in creating the individualized recommendations. We counted the number of uncompleted recommendations by age groups and examined the healthcare staff needed to address the recommendations and the potential patient effort needed to complete the recommendations. Results: For the 28,742 patients, there were 127,273 uncompleted recommendations identified for population health management (mean recommendations per patient 4.36, standard deviation of 2.65, range of 0–17 recommendations per patient). The age group with the most incomplete recommendations was age of 50–65 years with 5.5 recommendations per patient. The 18–35 years age group had the fewest incomplete recommendations with 2.6 per patient. Across all age groups, initiation of these recommendations required high-level input (physician, nurse practitioner, or physician’s assistant) in 28%. To completely adhere to recommended services, a 1000-patient cross-section cohort would require a total of 464 procedures and 1956 lab tests. Conclusion: Providers and patients face a daunting number of tasks necessary to meet guideline-generated recommendations. We will need new approaches to address the burgeoning numbers of uncompleted recommendations.
Advances in multidisciplinary therapy for meningiomas
Brastianos, Priscilla K. , Butowski, Nicholas , Chan, Jason W., Dunn, Ian F. , Goldbrunner, Roland , Ippen, Franziska M. , Mawrin, Christian , Sloan, Andrew E. , Snyder, James , Tabatabai, Ghazaleh , Tatagiba, Marcos, Wen, Patrick Y. , Aldape, Kenneth, Nassiri, Farshad , Zadeh, Gelareh , Jenkinson, Michael D. , Raleigh, David R. , Au, Karolyn , Barnhartz-Sloan, Jill, Butowski, N, Carlotti, Carlos Gilberto , Griffith, Brent, Hashizume, Rintaro , Hanemann, C. Oliver , Huang, Raymond Y. , Jungk, Christine, Kaufman, Timothy J, Krischek, Boris , Lee, Ian , Liu, Jeff C. , Mamatjan, Yasin , Mansouri, Alireza , Ng, Ho‐Keung , Pirouzmand, Farhad , Poisson, Laila , Pollo, Bianca , Sahm, Felix , Saladino, Andrea , Santarius, Thomas , Schichor, Christian , Selman, Warren R., Spears, Julian , Suppiah, Suganth , Tatagiba, Marcos, Tirapelli, Daniela, Tsang, Derek S. , Vogelbaum, Michael A. , Deimling, Andreas von , Walbert, Tobias , Westphal, Manfred , Workewych, Adriana M , Tatagiba, Marcos , Galanis, Evanthia , Mansouri, Alireza , von Deimling, Andreas , Sahm, Felix , Huang, Raymond , Lee, Ian Y , Herold‐Mende, Christel C. , McDermott, Michael , Tatagiba, Marcos , Tonn, Joerg-Christian , Wen, Patrick Yung , Bi, Wenya Linda , Cusimano, Michael D. , DiMeco, Francesco , Drummond, Katharine Jann , Giannini, Caterina , Horbinski, Craig , James, David, Jungk, Christine, Lachance, Daniel Honore , Fougère, Christian la , Muñoz, David G. , Noushmehr, Houtan , Perry, Arie , Schultz, David , Schmidt, Nils Ole , Hanemann, C Oliver , Mamatjan, Yasin

Mayo Clinic

Neuro-Oncology | September 17, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i18-i31

10.1093/neuonc/noy136 | PMID 30649489 Get It

Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration
Smith, Lucas D. , Smith, Andrew M. , Kohli, Manish , Smith, A M

Mayo Clinic

Journal of the American Chemical Society | September 14, 2018 | Volume: 140 | Issue: 42 | Pages: 13904-13912

10.1021/jacs.8b08879 | PMID 30215524 Get It

Sex Differences in Resting Metabolic Rate Among Athletes
Jagim, Andrew R. , Camic, Clayton L., Askow, Andy, Luedke, Joel, Erickson, Jacob L. , Jones, Margaret T. , Oliver, Jonathan M. , Askow, Andrew T. , Erickson, Jacob, Jagim, Andrew R , Askow, Andrew T , Kerksick, Chad M.

Mayo Clinic

Journal of Strength and Conditioning Research | September 8, 2018 | Volume: 33 | Issue: 11 | Pages: 3008-3014

10.1519/jsc.0000000000002813 | PMID 30199450 Get It

Abstract Jagim, AR, Camic, CL, Askow, A, Luedke, J, Erickson, J, Kerksick, CM, Jones, MT, and Oliver, JM. Sex differences in resting metabolic rate among athletes. J Strength Cond Res 33(11): 3008–3014, 2019—The purpose of this study was to compare differences in resting metabolic rate (RMR) between sexes in Division III National Collegiate Athletic Association (NCAA) collegiate athletes and to identify predictors of RMR. Sixty-eight male (M) (age: 20.1 ± 1.5 years; height: 181.8 ± 5.9 cm; body mass (BM): 93.7 ± 16.3 kg; and body fat%: 16.3 ± 8.6%) and 48 female (F) athletes (age: 19.4 ± 1.3 years; height: 166.5 ± 6.0 cm; BM: 63.4 ± 12.7 kg; and body fat%: 21.5 ± 6.3%) participated in a single day of testing, which included determination of RMR using indirect calorimetry and air displacement plethysmography to measure fat mass and fat-free mass (FFM). An independent-samples t -test was used to compare differences in body composition and RMR between sexes, and regression analysis was used to identify predictors of RMR. Men had a significantly higher absolute RMR (M: 2,481 ± 209 vs. F: 1,553 ± 193 kcals·d −1 ; p < 0.001), but when adjusted for BM (M: 25.6 ± 8.3 vs. F: 25.9 ± 2.5 kcals·kg −1 BM per day; p = 0.82) and FFM (M: 31.1 ± 10.6 vs. F: 33.6 ± 3.8 kcals·kg −1 FFM per day; p = 0.12), these differences became nonsignificant. Regression analysis indicated that BM in both men (β = 0.73) and women (β = 0.88) was the strongest predictor of RMR. The results of the current study indicate minimal differences in RMR between sexes among athletic populations when adjusted for BM and FFM. In the current group of athletes, BM seems to account for the largest variability in RMR.